Background {#Sec1}
==========

Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) has been reported to be positive in 5--10% of cases of renal injury complicated by infective endocarditis \[[@CR1]\]; however, histological findings have rarely been reported for these cases. In addition, the clinical course and optimal treatment have not been fully clarified.

We report a case of a patient with rapidly progressive PR3-ANCA-positive necrotizing crescentic glomerulonephritis complicated by *Streptococcus* infective endocarditis. The patient's renal disease improved with antibiotic therapy without any immunosuppressive agents, and his PR3-ANCA titer normalized in accordance with improving infective endocarditis.

Case presentation {#Sec2}
=================

Our patient was a 71-year-old Japanese man who had undergone the Bentall procedure and biological aortic valve replacement for the treatment of descending aortic aneurysm and aortic regurgitation at 70 years of age. Thereafter, his renal function had been normal (serum creatinine level, 0.93 mg/dl) without hematuria and proteinuria. Two months before admission, he had appetite loss, malaise, and gross hematuria. One month before admission, he noticed purpura on his lower extremities. A laboratory examination conducted by his primary care physician showed anemia (hemoglobin, 9.2 g/dl), thrombocytopenia (platelet count, 10 × 10^4^/μl), hematuria, and proteinuria. Therefore, he was referred to our hospital for further management.

Upon admission, his body temperature was 36.9 °C, and his blood pressure was 120/60 mmHg. Anemia, edema, and symmetrically distributed palpable purpura of the lower extremities were observed. He had no characteristic physical findings of infective endocarditis, such as Osler nodes, Roth spots, and Janeway lesions. Cardiac auscultation revealed 2/6 systolic reflux murmur at the cardiac apex. Blood analysis showed that the patient's serum creatinine level was elevated at 2.34 mg/dl, and his serum hemoglobin level was reduced at 7.6 g/dl. Urinalysis showed proteinuria at 0.74 g/g Cr and microscopic hematuria. PR3-ANCA level was elevated at 163 IU/ml (normal range, \< 10 IU/ml). The patient had negative test results for hepatitis B antigen, hepatitis C antibody, cryoglobulin, antistreptolysin O, antinuclear antibody, immune complex, and myeloperoxidase-ANCA. Serum complement C3 was mildly decreased, whereas C4 was normal. Laboratory data obtained at admission are summarized in Table [1](#Tab1){ref-type="table"}. No abnormalities were found in the patient's chest x-ray or electrocardiogram. *Streptococcus* species was detected from two separate blood culture bottles. On the third hospital day, renal biopsy was performed. Histological analysis revealed that 54% (6 of 11) of glomeruli showed partial fibrinoid necrosis with fragmentation of glomerular tufts (Fig. [1](#Fig1){ref-type="fig"}a), and 27% (3 of 11) of glomeruli showed cellular crescents (Fig. [1](#Fig1){ref-type="fig"}b). No fibrocellular or fibrous crescents and no endocapillary proliferation were found. The mesangium showed no increase in cells or matrix. The tubulointerstitium partially showed neutrophilic and lymphocytic infiltration in the peritubular capillary and atrophy (Fig. [1](#Fig1){ref-type="fig"}c). Fibrinoid necrosis was not observed in vessel walls. Immunofluorescence microscopy showed no deposition of immunoglobulins and complement factors. Electron microscopy showed small amounts of nonspecific electron-dense deposits in subendothelial areas and the paramesangial area. At this point, the patient met the modified Duke criteria for definitive infective endocarditis \[[@CR2]\] (mitral valve vegetation on echocardiography, two positive blood cultures of *Streptococcus* species drawn 3 days apart, glomerulonephritis). On the eighth hospital day, transesophageal echocardiography revealed mitral valve vegetation. On the 12th hospital day, spinal magnetic resonance imaging showed pyogenic spondylitis at T7/T8 and L4/L5. On the basis of these findings, the patient was diagnosed with rapidly progressive PR3-ANCA-positive necrotizing crescentic glomerulonephritis complicated by *Streptococcus* infective endocarditis. Antibiotic therapy including cefazolin and penicillin G followed by oral administration of ampicillin was provided without immunosuppressive agents. Thereafter, his renal disease, endocarditis, and pyogenic spondylitis improved. He was discharged from our center on the 73rd hospital day. He has since received regular outpatient treatment in our department. At 7 months after discharge, his serum creatinine level had decreased to 1.43 mg/dl, his proteinuria had decreased to 0.15 g/g Cr, and his hematuria had decreased to 1.1 red blood cells per high-power field. His PR3-ANCA level had decreased to within the normal range (Fig. [2](#Fig2){ref-type="fig"}). Table 1Laboratory findings upon admissionComplete blood count and blood chemistryValueWBC13,600/μL Bands2% Segments82% Eosinophils0% Basophils0% Lymphocytes7% Monocytes8%RBC323 × 10^4^/μLHemoglobin7.6 g/dLHematocrit29.2%Platelet12.0 × 10^4^/μLTotal protein7.0 g/dLAlbumin2.6 g/dLAST35 IU/LALT23 IU/LCRP7.57 mg/dLNa^+^130 mmol/LK^+^5.3 mmol/LCl^−^101 mmol/LCa^2+^7.7 mg/dLPhosphate3.8 mg/dLBUN25 mg/dLCr2.52 mg/dLeGFR20.8 ml/minute/1.73 m^2^Uric acid6.3 mg/dLHbA1c6.3%Glucose106 mg/dLASO73 IU/mLHepatitis B antigen\< 0.04Hepatitis C antibody\< 0.29 IgG2692 mg/dL IgA340 mg/dL IgM350 mg/dL Anti-DNA antibody\< 10 Anti-RNP antibodyNegative Anti-Sm antibodyNegative C350 mg/dL C417 mg/dL CH5023.4 U/mL Antinuclear antibody160 PR3-ANCA163 IU/mL MPO-ANCA\< 1.0 IU/mL Anti-GBM antibody\< 2.0 IU/mL ESR86 mm/hour Rheumatoid factor86 IU/mLUrinary analysis RBCNumerous (dysmorphic)/HPF WBC1--4/HPF Protein0.74 g/g Cr β~2~-MG12,133 μg/L*Abbreviations*: *ALT* alanine aminotransferase, *ASO* antistreptolysin O, *AST* aspartate aminotransferase, *β*~*2*~*-MG* β~2~-microglobulin, *BUN* blood urea nitrogen, *CH50* 50% homolytic unit of complement, *Cr* creatinine, *CRP* C-reactive protein, *C3* complement component 3, *C4* complement component 4, *eGFR* estimated glomerular filtration rate, *ESR* erythrocyte sedimentation rate, *GBM* antiglomerular basement membrane antibody, *HbA1c* hemoglobin A1c, *HPF* high-power field, *Ig* immunoglobulin, *MPO-ANCA* myeloperoxidase antineutrophil cytoplasmic antibody, *PR3-ANCA* proteinase 3 antineutrophil cytoplasmic antibody, *RBC* red blood cells, *RNP* ribonucleoprotein, *Sm* Smith, *WBC* white blood cells Fig. 1Renal biopsy findings. **a** Glomerulus with partial fibrinoid necrosis with fragmentation of glomerular tufts (*arrows*) (periodic acid-methenamine silver stain; original magnification, 400×). **b** Glomerulus with cellular crescentic formation (*arrows*) (periodic acid-Schiff stain; magnification, original magnification, 400×). **c** Tubulointerstitium with sporadic neutrophil infiltration in the peritubular capillary (*arrows*) and atrophy (*broken line*) (periodic acid-Schiff stain; original magnification, 100×) Fig. 2The patient's clinical course. *ABPC* Ampicillin, *CEZ* Cefazolin, *Cr* Creatinine, *PCG* Penicillin G, *PR3-ANCA* Proteinase 3-antineutrophil cytoplasmic antibody

Discussion and conclusions {#Sec3}
==========================

We report a case of rapidly progressive PR3-ANCA-positive necrotizing crescentic glomerulonephritis complicated by *Streptococcus* infective endocarditis. The patient's renal disease improved with antibiotic monotherapy, which led to normalization of PR3-ANCA titer in accordance with improving infective endocarditis.

Renal disease associated with infective endocarditis shows various pathological changes including crescent formation, fibrinoid necrosis, mesangial cell proliferation, and endothelial cell thickening in the glomerulus and tubulointerstitial damage with infiltration of immune cells \[[@CR3]--[@CR7]\]. PR3-ANCA has been reported to be positive in 5--10% of cases of renal disease complicated with infective endocarditis \[[@CR1]\]. It is considered that PR3-ANCA may be produced as a result of an immune response against infection by sharing epitopes with cytoplasmic antigens of neutrophils in cases of infective endocarditis \[[@CR8]\]. The produced PR3-ANCA is then speculated to contribute to fibrinoid necrosis, crescent formation, and granulomas in the kidney \[[@CR9]\]. However, the lack of sufficient histological findings of PR3-ANCA-positive renal diseases complicated by infective endocarditis prevents clarification of detailed pathological changes in the kidney. Although many cases of PR3-ANCA-positive renal disease complicated by infective endocarditis have been reported, including crescentic glomerulonephritis, endocapillary proliferative glomerulonephritis, mesangial proliferative glomerulonephritis, and focal segmental glomerulonephritis, only three cases showed necrotizing crescentic glomerulonephritis complicated by infective endocarditis \[[@CR10]--[@CR34]\] (Table [2](#Tab2){ref-type="table"}). Regarding treatment for PR3-ANCA-positive renal disease complicated by infective endocarditis, previous studies suggested antibiotic monotherapy for patients with low PR3-ANCA titers (\< 25 IU/ml) and combination therapy with immunosuppressive agents, including steroids for patients with high PR3-ANCA titers (\> 50 IU/ml), when the patients' condition does not improve with antibiotic monotherapy \[[@CR22], [@CR35]\]. The three previous cases of PR3-ANCA-positive necrotizing crescentic glomerulonephritis showed various PR3-ANCA titers (2.96, \> 8.0, and 85 IU/ml) and were treated with immunosuppressive agents such as corticosteroids in addition to antibiotics. Among those three cases, the renal disease resolved completely in two patients but progressed to end-stage renal disease in the other (Table [2](#Tab2){ref-type="table"}). The other types of PR3-ANCA-positive renal disease complicated by infective endocarditis also showed various PR3-ANCA titers (3--359 IU/ml) and were treated with antibiotics with or without immunosuppressive agents (Table [2](#Tab2){ref-type="table"}). Regarding treatment outcomes, most renal diseases recovered, except for one patient with crescentic glomerulonephritis with high PR3-ANCA titers (247 IU/ml) and one patient with mesangial proliferative glomerulonephritis with high PR3-ANCA titers (143 IU/ml), both of whom died (Table [2](#Tab2){ref-type="table"}). In our patient, necrotizing crescentic glomerulonephritis improved with antibiotic monotherapy, and PR3-ANCA titer normalized in accordance with improving infective endocarditis; however, PR3-ANCA titer was highly elevated at 163 IU/ml. The results of our patient's case suggest that antibiotic monotherapy can be effective even if the PR3-ANCA titer is considerably high in PR3-ANCA-positive necrotizing crescentic glomerulonephritis complicated by infective endocarditis. However, caution is needed with the use of immunosuppressive agents because they may exacerbate bacteremia and infective endocarditis. Furthermore, a greater accumulation of cases with histological evidence is needed to investigate optimal treatments for PR3-ANCA-positive renal disease complicated with infective endocarditis. Table 2Case reports of PR3-ANCA-positive renal injury complicated by infective endocarditisAge (years)/sexRenal biopsy histology (IF/EM)PR3-ANCA (IU/mL)Microbe detectedPast medical historyTreatmentsOutcomeReference54/MFocal necrotizing crescentic GN(negative/no deposits)2.96*Streptococcus mutans*MVPPiperacillin, tazobactam, cyclophosphamide, corticosteroidsComplete recovery\[[@CR10]\]59/MFocal necrotizing crescentic GN(negative/no deposits)\> 8.0*Enterococcus faecalis*Hepatitis B and CPulse methylprednisolone ⇒ prednisoloneHemodialysis\[[@CR11]\]67/MFocal necrotizing crescentic GN(IgA^+^, IgM^+^, IgG^+^, C3^+^, C1q^+^/mesangial and subendothelial dense deposits)85*Gemella sanguinis*No mentionCeftriaxone, gentamicin, methylprednisoloneTemporary hemodialysis ⇒ complete recovery\[[@CR12]\]6/MCrescentic GN(no mention)Positive*Bartonella henselae*CHDDoxycycline, rifampicinNo mention\[[@CR13]\]12/FCrescentic GN(C3^+^/subendothelial dense deposits)Positive*Gemella morbillorum*NothingPenicillin, gentamicin, steroidsComplete recovery\[[@CR14]\]14/MCrescentic GN(no mention)Positive*Bartonella henselae*CHDDoxycyclineNo mention\[[@CR13]\]18/FCrescentic GN(IgG\[1+\], IgM\[3+\], C3\[2+\], C1q\[2+\]/subendothelial dense deposits)32*Bartonella henselae*Tetralogy of Fallot, SSS, and complete heart blockAntibiotic therapy, methylprednisoloneComplete recovery\[[@CR15]\]24/MCrescentic GN(C3^+^/mesangial and subendothelial dense deposits)14α-Hemolytic *Streptococcus*VSDCefotaxime, prednisoloneNo renal dysfunction\[[@CR16]\]26/FCrescentic GN(IgM^+^ C3^+^/no mention)160*Streptococcus viridans*ASD, recent dental TxPenicillin G, tobramycinRecovery\[[@CR17]\]36/MCrescentic GN(negative/no mention)359*Bartonella henselae*No mentionPrednisolone, intravenous cyclophosphamide ⇒ azathioprine, MMF, prednisolone, CV surgeryComplete recovery\[[@CR18]\]43/MCrescentic GN(negative/no mention)Positive*Bartonella henselae*Infective endocarditis (blood culture was negative)Cyclophosphamide, prednisoloneCV surgeryNo mention\[[@CR19]\]46/MCrescentic GN(C3^+^ C1q^+^/no mention)25NegativeNo mentionAmoxicillin, gentamicin, penicillinComplete recovery\[[@CR20]\]47/MCrescentic GN(IgM^+^, IgA^+^, C3^+^, C1q^+^/mesangial and subendothelial dense deposits)160*Bartonella henselae*Cat scratch diseaseDoxycycline, rifampicin 6 weeksRecovery\[[@CR21]\]50/MCrescentic GN(negative/not performed)247*Streptococcus oralis*NothingSteroid therapy ⇒ ampicillin, gentamicin, vancomycinDeath\[[@CR22]\]54/MCrescentic GN(IgM^+^, C3^+^/no deposits)3*Streptococcus mutans*No mentionAmpicillin ⇒ vancomycin, corticosteroids, cyclophosphamideRecovery\[[@CR23]\]55/MCrescentic GN(C3\[2+\], IgA^+^/no deposits)\> 8.0*Bartonella henselae, Bartonella quintana*DepressionVancomycin, cefepime ⇒ doxycycline, rifampicin, methylprednisoloneRecovery\[[@CR24]\]67/MCrescentic GN(IgM^+^, C3^+^, C1q^+^/no mention)41*Bartonella henselae*Thoracic aortic aneurysm repairRifampicin, doxycycline, methylprednisoloneTemporary hemodialysis ⇒ recovery\[[@CR25]\]72/FCrescentic GN(no mention)Positive*Aggregatibacter aphrophilus*No mentionVancomycin, ceftriaxoneTemporary hemodialysis ⇒ recovery\[[@CR26]\]42/MDiffuse endocapillary proliferative GN(C3^+^/subendothelial dense deposits)21.3*Staphylococcus aureus*NothingCefazolinRecovery\[[@CR27]\]68/MDiffuse endocapillary proliferative GN and crescentic GN(IgG\[2+\], IgM\[3+\], C3\[3+\], C1q\[2+\]/subendothelial dense deposits)102NegativeSchistosomiasisCefoperazone, tazobactamComplete recovery\[[@CR28]\]78/FEndocapillary proliferative GN(IgM^+^, C3^+^, C1q^+^/no mention)30*Bartonella henselae*HypertensionDoxycyclineComplete recovery\[[@CR29]\]48/MMesangial proliferative GN(C3^+^/no mention)12NegativeAlcoholism, DMAmoxicillin, gentamicinComplete recovery\[[@CR20]\]57/MMesangial proliferative GN(IgG^+^, IgM^+^, C3^+^ /no mention)45NegativeNothingCorticosteroids ⇒ ampicillin, ceftriaxone, gentamicin, vancomycinRecovery\[[@CR30]\]74/MMesangial proliferative GN(IgG^+^, C1q^+^/not performed)\> 100*Bartonella henselae, Bartonella quintana*IHD, pacemaker, DM, pulmonary embolusAntibiotic therapyRecovery\[[@CR31]\]78/MMesangial proliferative GN(IgM^+^, C3^+^, IgA^+^, C1q^+^/subendothelial dense deposits)143*Enterococcus faecalis*Coronary artery bypass surgeryAntibiotic therapyDeath\[[@CR32]\]57/MFSGS(IgM^+^, C3^+^/paramesangial dense deposits)40NegativeDM, AVR, aortic aneurysmPulse methylprednisolone ⇒ vancomycin, gentamicin, rifampicinPlasmapheresis ⇒ recovery\[[@CR33]\]64/MFSGS and mild interstitial inflammation(no mention)60NegativeInsidious mild renal dysfunctionCeftriaxone, doxycyclineComplete recovery\[[@CR34]\]*Abbreviations*: *ASD* atrial septal defect, *AVR* aortic valve replacement, *CHD* chronic heart disease, *C3* complement component 3, *CV* cardiovascular, *DM* diabetes mellitus, *EM* electron microscopy, *F* female, *FSGS* focal segmental glomerulonephritis, *GN* glomerular nephritis, *IF* immunofluorescence, *IHD* ischemic heart disease, *Ig* immunoglobulin, *LM* light microscopy, *M* male, *MMF* mycophenolate mofetil, *MVP* mitral valve prolapse, *PR3-ANCA* proteinase 3 antineutrophil cytoplasmic antibody, *SSS* sick sinus syndrome, *Tx* treatment, *VSD* ventricular septal defect

In conclusion, we describe a case of a patient with PR3-ANCA-positive necrotizing crescentic glomerulonephritis complicated by infective endocarditis. His renal disease was improved with antibiotic agents, and his PR3-ANCA titer normalized in accordance with improving infective endocarditis.
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